We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
SPDR S&P Telecom ETF | AMEX:XTL | AMEX | Exchange Traded Fund |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.0098 | -0.01% | 70.3494 | 70.4992 | 69.97 | 69.97 | 987 | 21:15:00 |
XTLbio Announces Purchase of 14% Stake by Israel Healthcare Ventures Rehovot, Israel, 17 July 2003 - XTL Biopharmaceuticals Ltd. (XTLbio) confirms today that it has been informed by Israel Healthcare Ventures (IHCV), a venture capital fund committed to investing in Israeli-based companies in the life sciences and medical technology field, that IHCV has acquired a 14% shareholding in XTLbio. IHCV was founded in March 2001 by UK and US private investors with pharmaceutical and financial backgrounds - Isaac Kaye Family Trust, Harvey Kruger, Steven Kaye and Warren Roiter. Since its launch, it has invested in a number of innovative Israeli companies that have the potential for rapid market penetration and profitability. Hadar Ron, Managing Director of IHCV, said: "XTLbio exactly fits our strict investment criteria. It is a company focused on innovative science in an area of significant and increasing unmet medical need. We are enthusiastic about its prospects." Martin Becker, Chief Executive of XTLbio, added: "We are very pleased to have the support from investors of the calibre of IHCV. Their commitment highlights the promise of XTLbio and our work in finding drugs to overcome hepatitis." Contacts: XTLbio - Tel: +972-(0)8-930-4444 Martin Becker, Chief Executive Officer Jonathan Burgin, Chief Financial Officer Financial Dynamics - Tel: +44-(0)20-7831-3113 David Yates NOTES About XTLbio XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing drugs against hepatitis. XTLbio's HepeX(tm) product line - now in clinical trials - has the potential to introduce revolutionary therapies for viral hepatitis, including prevention of re-infection in transplanted livers, the Company's primary focus, and a longer-term cocktail approach in treating chronic illness. XTLbio believes its primary competitive advantage lies in its patented Trimera(tm) technology, which enables the development of fully human monoclonal antibodies and models of human disease for pre-clinical drug validation. Established in 1993, XTLbio became a public company in 2000 with shares traded on the London Stock Exchange under the symbol XTL. About Israel Healthcare Ventures Israel Healthcare Ventures (IHCV), managed by Dr. Hadar Ron in Israel, provides venture capital investment to Israeli and Israeli related companies in the fields of medical devices, biotechnology, pharmaceuticals, and medical-related IT. Headquartered in Tel Aviv, IHCV was founded in March 2001 by prominent US and UK investors from the pharmaceutical and financial services worlds. It is led by highly experienced medical analysts and advisors. IHCV takes a hands-on approach, providing portfolio companies with clinical advice, management consulting and an extensive network of contacts throughout the global medical and financial fields. They take a close look at the underlying science, the particular characteristics of the target market, and the quality of the management. Their ideal investment opportunity is a company with truly innovative technology that provides a solution to an existing need, and that has excellent potential for rapid market acceptance and profitability. The company should be led by highly competent, experienced people who have the flexibility to adapt to problems, challenges and opportunities as they arise. END
1 Year SPDR S&P Telecom ETF Chart |
1 Month SPDR S&P Telecom ETF Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions